Literature DB >> 12950025

Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping.

Nadia Zaffaroni1, Daniela De Polo, Raffaella Villa, Chiara Della Porta, Paola Collini, Alessandra Fabbri, Silvana Pilotti, Maria Grazia Daidone.   

Abstract

Telomerase activity was examined by the telomeric repeat amplification protocol (TRAP) assay in 38 neuroendocrine (NE) lung tumours. A significantly (p = 0.001) different frequency of telomerase positivity was observed among different histological tumour types. Specifically, a positive TRAP signal was observed in 14 of 15 (93%) small cell lung cancers (SCLCs), 7 of 8 (87%) large-cell NE carcinomas (LCNECs), and only 1 of 15 (7%) typical carcinoid tumours. When telomerase activity was correlated with the gene product-based immunophenotypic profile of individual tumours, it was found that the absence of telomerase activity was associated with a lack of bcl-2, p53, and c-kit expression, and characterized by a low proliferation index consistent with the absence of cdk-4 expression and the presence of the cdk inhibitor Rb. Such a phenotype was appreciable in most of the carcinoid tumours. Conversely, telomerase-positive tumours generally showed an immunophenotype consistent with gene product alterations (including high expression of bcl-2, p53, and c-kit, and loss of Rb) and were characterized by a high proliferation index. These telomerase data support the previously reported evidence for two genetically unrelated groups of NE lung tumours (SCLC, and to some extent LCNEC, versus carcinoid tumours) that have distinct phenotypic profiles. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950025     DOI: 10.1002/path.1401

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  RNAi targeting of hTERT gene expression induces apoptosis and inhibits the proliferation of lung cancer cells.

Authors:  Linhu Ge; Wenlong Shao; Yangde Zhang; Yuan Qiu; Dong Cui; Donghai Huang; Zhansheng Deng
Journal:  Oncol Lett       Date:  2011-08-19       Impact factor: 2.967

Review 2.  Treatment of lung large cell neuroendocrine carcinoma.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Claudia Proto; Marianna Macerelli; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Rosaria Gallucci; Nicoletta Zilembo; Marco Platania; Roberto Buzzoni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-03-04

3.  Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.

Authors:  Christopher M Heaphy; Michael C Haffner; Mindy K Graham; David Lim; Christine Davis; Eva Corey; Jonathan I Epstein; Mario A Eisenberger; Hao Wang; Angelo M De Marzo; Alan K Meeker; Tamara L Lotan
Journal:  Hum Pathol       Date:  2020-05-07       Impact factor: 3.466

4.  Telomerase activation in small intestinal neuroendocrine tumours is associated with aberrant TERT promoter methylation, but not hot-spot mutations.

Authors:  Omid Fotouhi; Mehran Ghaderi; Na Wang; Jan Zedenius; Magnus Kjellman; Dawei Xu; C Christofer Juhlin; Catharina Larsson
Journal:  Epigenetics       Date:  2019-07-19       Impact factor: 4.528

Review 5.  Treatment options for patients with large cell neuroendocrine carcinoma of the lung.

Authors:  Akira Iyoda; Takashi Makino; Satoshi Koezuka; Hajime Otsuka; Yoshinobu Hata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-04-10

6.  Rs2853677 modulates Snail1 binding to the TERT enhancer and affects lung adenocarcinoma susceptibility.

Authors:  Xiaoting Li; Xing Xu; Jiali Fang; Lin Wang; Yanchao Mu; Peng Zhang; Zhi Yao; Zhenyi Ma; Zhe Liu
Journal:  Oncotarget       Date:  2016-06-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.